Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Immunol. 2017 Nov 17;200(1):130–138. doi: 10.4049/jimmunol.1700229

Figure 7. Reduced monocyte migration into the ankles following infliximab treatment.

Figure 7

(A). Infliximab suppresses the monocyte influx into ankles in hTNF-Tg mice. Monocytes isolated from CD45.1 bone marrow were transferred into TNF-Tg (CD45.2) mice. The TNF-Tg recipients were received one dose of infliximab 24 hours before and additional dose at the same time of monocyte administrated (2 doses), or a single dose at the same time as monocytes were injected (1 dose). All mice were sacrificed 24 hours after monocyte injection, and analyzed for CD45.1 cells in the ankle joints. The panels on the left are representative gating of the CD45.1+CD45.2- donor monocytes that migrated into the ankles (indicated by arrows), with the statistical analysis presented in the panels on the right (n = 4-5 mice for each group). (B). Reduced CCL2 and CXCL5, but not CX3CL1 in the ankles of hTNF-Tg mice following treatment with infliximab (2 doses), determined by ELISA (n = 7-8 mice for each group). *** represents p < 0.001 between the indicated groups.